The Ross Prize in Molecular Medicine was established in conjunction with the Feinstein Institutes for Medical Research and Molecular Medicine to recognize biomedical scientists whose discoveries have transformed how medicine is practiced.
The awardees are mid-career researchers who have significantly impacted the understanding of human disease pathogenesis and/or treatment. Moreover, it is anticipated that they will continue to make profound advances in the general field of molecular medicine.
The 13th annual Ross Prize in Molecular Medicine is awarded jointly to Drs. Carl June and Michel Sadelain for their pioneering work in developing CAR T-cell therapy for cancer treatment.
Dr. June’s and Sadelain’s complementary work has led to the groundbreaking form of personalized cancer immunotherapy that modifies T cells from a patient’s immune system with synthetic receptors called chimeric antigen receptors (CARs). These receptors enable them to recognize and selectively destroy cancer cells when infused back into the patient’s body. CAR T-cell technology has revolutionized how physicians treat leukemia, lymphoma, and multiple myeloma, and is now showing promise in treating autoimmune and infectious diseases.
Join us in celebrating Dr. June’s and Dr. Sadelain’s innovative, award-winning research on June 11th.
This hybrid symposium will include presentations from Dr. June and Dr. Sadelain on the integral facets of their work, plenary lectures, and in-person networking opportunities. Register today to participate in this incredible celebration of scientific innovation.
This symposium is made possible by the generosity of Jack and Robin Ross with support from:
